Pipeline

SQUADRA Pipeline

  • 00
    Holding

    SQUADRA Network

  • 01
    Holding

    DD
    7 Solutions

  • 02
    Holding

    Pre-Seed

  • 04
    Holding

    Seed

  • 05
    Holding

    Portfolioco Spin-Off

  • 06
    Portfolioco

    Series A

  • 07
    Portfolioco

    Series B

  • 00
    Holding

    SQUADRA Network

  • 01
    Holding

    DD
    7 Solutions

  • 02
    Holding

    Pre-Seed

  • 04
    Holding

    Seed

  • 05
    Holding

    Portfolioco Spin-Off

  • 06
    Portfolioco

    Series A

  • 07
    Portfolioco

    Series B

Antonello Fazio

Project Lead
Seed Stage

Scott Parazynski, MD

Project Lead
Pre-Seed Stage

Eng. Maria Aboytes

Project Lead
Pre-Seed Stage

2022 Portfolio

Pre-Seed &
Seed Stage

Antonello Fazio

Project Lead
Seed Stage

PROBLEM

The current invasive surgical treatment for ascending aortic aneurisms is very high risk with up to 80% mortality rates.

INNOVATIVE SOLUTION

Developing the first non-invasive device for the treatment of ascending aorta aneurisms and dissections, which is a deadly heart condition.

INVESTMENT OPPORTUNITY

Market size: $1.7B
Non-dilutive funding approved $1M

TARGET EXIT STRATEGY

M&A in 2027: $350M

Scott Parazynski, MD

Project Lead
Pre-Seed Stage

PROBLEM

Sensitive and specific diagnostic, imaging and therapeutic options for deadly cancers like glioblastoma do not exist.

INNOVATIVE SOLUTION

Highly targeted, stable aptamers allow us to bind glioblastoma stem cells, and will lead to screening blood tests, theragnostics and payload delivery for better outcomes.

INVESTMENT OPPORTUNITY

Market size: $4.2B (by 2028)

TARGET EXIT STRATEGY

M&A in 2028: $450M

Eng. Maria Aboytes

Project Lead
Pre-Seed Stage

PROBLEM

60% post ischemic stroke treatment disability.

INNOVATIVE SOLUTION

Developing the first device to treat ischemic stroke in first pass (time saving = reduced mortality/disability rates) and more effectively (targeting soft, medium, and hard clots that currently are an unmet need).

INVESTMENT OPPORTUNITY

Market size: $1B (by 2028)

TARGET EXIT STRATEGY

M&A in 2027: $350M

SQUADRA shows what’s possible when a necessity meets vision and competence.

Connect with us
on LinkedIn.

Visit our profile

What's new at SQUADRA?

Get the latest news about
medtech and investments.

What's new at Squadra?